William J. Muller

ORCID: 0000-0001-7690-0695
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HER2/EGFR in Cancer Research
  • Herpesvirus Infections and Treatments
  • Cancer Cells and Metastasis
  • PI3K/AKT/mTOR signaling in cancer
  • Cytomegalovirus and herpesvirus research
  • COVID-19 Clinical Research Studies
  • Cytokine Signaling Pathways and Interactions
  • SARS-CoV-2 and COVID-19 Research
  • Cancer Immunotherapy and Biomarkers
  • Respiratory viral infections research
  • Protein Tyrosine Phosphatases
  • Lung Cancer Treatments and Mutations
  • Antifungal resistance and susceptibility
  • Immunotherapy and Immune Responses
  • Cancer-related molecular mechanisms research
  • Mechanisms of cancer metastasis
  • CAR-T cell therapy research
  • Virus-based gene therapy research
  • Viral gastroenteritis research and epidemiology
  • Monoclonal and Polyclonal Antibodies Research
  • NF-κB Signaling Pathways
  • Polyomavirus and related diseases
  • Pneumonia and Respiratory Infections
  • Fungal Infections and Studies
  • Wnt/β-catenin signaling in development and cancer

Lurie Children's Hospital
2015-2025

Northwestern University
2016-2025

University of Illinois Chicago
2025

McGill University
2009-2023

Pediatrics and Genetics
2012-2021

Occupational Cancer Research Centre
2012-2020

Seattle Children's Hospital
2014

University of Washington
2005-2014

University of Georgia
2007

Luzerner Kantonsspital
2006

The effect of mammary gland-specific expression the polyomavirus middle T antigen was examined by establishing lines transgenic mice that carry oncogene under transcriptional control mouse tumor virus promoter/enhancer. By contrast to most strains carrying activated oncogenes, resulted in widespread transformation epithelium and rapid production multifocal adenocarcinomas. Interestingly, majority tumor-bearing developed secondary metastatic tumors lung. Taken together, these results suggest...

10.1128/mcb.12.3.954 article EN Molecular and Cellular Biology 1992-03-01

Abstract Background There are many pharmacologic therapies that being used or considered for treatment of coronavirus disease 2019 (COVID-19). is a need frequently updated practice guidelines on their use, based critical evaluation rapidly emerging literature. The objective was to develop evidence-based rapid intended support patients, clinicians, and other healthcare professionals in decisions about management patients with COVID-19. Methods Infectious Diseases Society America (IDSA) formed...

10.1093/cid/ciaa478 article EN other-oa Clinical Infectious Diseases 2020-04-22

The effect of mammary gland-specific expression the polyomavirus middle T antigen was examined by establishing lines transgenic mice that carry oncogene under transcriptional control mouse tumor virus promoter/enhancer. By contrast to most strains carrying activated oncogenes, resulted in widespread transformation epithelium and rapid production multifocal adenocarcinomas. Interestingly, majority tumor-bearing developed secondary metastatic tumors lung. Taken together, these results suggest...

10.1128/mcb.12.3.954-961.1992 article EN Molecular and Cellular Biology 1992-03-01

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy safety nirsevimab healthy late-preterm term infants are uncertain.

10.1056/nejmoa2110275 article EN New England Journal of Medicine 2022-03-02

This cohort study investigates age-related differences in nasopharyngeal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) levels patients with mild to moderate disease 2019 (COVID-19).

10.1001/jamapediatrics.2020.3651 article EN JAMA Pediatrics 2020-07-30

Abstract There are many pharmacologic therapies that being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended support patients, clinicians, other healthcare professionals in their decisions about management patients COVID-19. In March 2020, the Infectious Diseases Society America (IDSA) formed a multidisciplinary guideline panel...

10.1093/cid/ciac724 article EN Clinical Infectious Diseases 2022-09-05

The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown.Part 1 this ongoing phase 2-3 trial was open label for dose selection; part 2 an observer-blinded, placebo-controlled evaluation selected dose. In 2, we randomly assigned (6 months to 5 years age) a 3:1 ratio receive two 25-μg injections or placebo, administered 28 days apart. primary objectives were evaluate safety reactogenicity determine...

10.1056/nejmoa2209367 article EN New England Journal of Medicine 2022-10-19

To characterize nirsevimab in the prevention of RSV, children from Phase 3 MELODY trial were followed through their second RSV season. No increase medically attended lower respiratory tract infections or evidence antibody-dependent enhancement infection disease severity was found for vs placebo recipients. Clinical Trial Registration: Clinicaltrials.gov, NCT03979313, https://clinicaltrials.gov/ct2/show/NCT03979313.

10.1093/jpids/piad113 article EN cc-by Journal of the Pediatric Infectious Diseases Society 2024-01-14

Pediatric patients frequently present with illnesses strongly suggesting infection, but without a clearly identified etiology. Our center has recently added commercially available plasma metagenomic sequencing assay to its diagnostic testing. experience the first 100 tests suggests that this technology good clinical performance >90% sensitivity.

10.1093/ofid/ofz327 article EN cc-by-nc-nd Open Forum Infectious Diseases 2019-07-12

Abstract Background We sought to determine if next‐generation sequencing (NGS) of microbial cell‐free DNA (cfDNA) in plasma would detect pathogens pediatric patients at risk for invasive fungal disease (IFD). Procedures Pediatric hematology, oncology, and stem cell transplant deemed new IFD had blood samples drawn three time‐points separated by 1‐month intervals. The primary outcome measure was detection compared standard clinical testing. Secondary outcomes included identification other...

10.1002/pbc.27734 article EN cc-by Pediatric Blood & Cancer 2019-04-02

The distribution of upper respiratory viral loads (VL) in asymptomatic children infected with severe acute syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed PCR cycle threshold (Ct) values and estimated VL diagnosed nine pediatric hospital testing programs. Records for symptomatic patients positive clinical SARS-CoV-2 tests were reviewed. Ct (i) adjusted by centering each value around the institutional median from tested that assay (ii) converted to (numbers copies per milliliter)...

10.1128/jcm.02593-20 article EN Journal of Clinical Microbiology 2020-10-23

To define the minimal cis-acting sequences required for polyomavirus DNA replication (ori), we constructed a number of polyomavirus-plasmid recombinants and measured their replicative capacity after transfection permissive mouse cell line capable providing large T antigen in trans (MOP cells). Recombinant plasmids containing 251-base-pair fragment noncoding viral replicate efficiently MOP cells. Mutational analyses these revealed that they can be physically separated into two genetic...

10.1128/jvi.47.3.586-599.1983 article EN Journal of Virology 1983-09-01

Objective: To estimate the association of age viral suppression and central nervous system penetration effectiveness (CPE) score with neurocognitive functioning among school-age children perinatally acquired HIV infection (PHIV+). Design: We analyzed data from two US-based multisite prospective cohort studies. Methods: Multivariable general linear regression models were used to evaluate associations at CPE scores (of initial antiretroviral therapy regimen weighted average) Wechsler...

10.1097/qad.0000000000000528 article EN AIDS 2014-12-04

This study represents the largest compilation to date of clinical and postmortem data from decedents with coronavirus disease 2019 (COVID-19). It will augment previously published small series autopsy case reports, refine clinicopathologic considerations, improve accuracy future vital statistical reporting.To accurately reflect preexisting diseases pathologic conditions SARS-CoV-2 (severe acute respiratory syndrome 2) infection through autopsy.Comprehensive 135 evaluations COVID-19-positive...

10.5858/arpa.2020-0786-sa article EN Archives of Pathology & Laboratory Medicine 2021-01-15

Isavuconazole, administered as the water-soluble prodrug isavuconazonium sulfate, is a new triazole agent used to treat invasive fungal infections. This phase 1 study evaluated pharmacokinetics (PK), safety, and tolerability of isavuconazole in 46 immunocompromised pediatric patients, stratified by age (1 <6 [intravenous (i.v.) only], 6 <12, 12 <18 years), receiving 10 mg/kg body weight (maximum, 372 mg) sulfate either i.v. or orally.

10.1128/aac.00290-21 article EN cc-by Antimicrobial Agents and Chemotherapy 2021-05-20

Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT patients, 18 whom had severe manifestations infection. Cidofovir treatment led to clinical improvement 8 10 patients with infection and virologic clearance 9 patients. In vitro susceptibility cidofovir was demonstrated 12 isolates. is a promising option for this population.

10.1086/498151 article EN Clinical Infectious Diseases 2005-11-18

O bjectives : The aim of the study was to investigate presence serum antibodies different Leptospira serogroups in dogs with a clinical diagnosis leptospirosis southern Germany and compare seroreactivity history, signs, laboratory findings survival rate. M ethods In this study, data 42 were evaluated retrospectively. Dogs presented Small Animal Medicine Teaching Hospital (Medizinische Kleintierklinik) Ludwig Maximilians University Munich, Germany, between 1990 2003. R esults Reactivity...

10.1111/j.1748-5827.2007.00324.x article EN Journal of Small Animal Practice 2007-05-08

Abstract Bcl3 is a putative proto-oncogene deregulated in hematopoietic and solid tumors. Studies cell lines suggest that its oncogenic effects are mediated through the induction of proliferation inhibition death, yet role endogenous tumors has not been established. Here, we address effect vivo describe how this Stat3-responsive oncogene promotes metastasis ErbB2-positive mammary without affecting primary tumor growth or normal function. Deletion gene (MMTV-Neu) mice resulted 75% reduction...

10.1158/0008-5472.can-12-1321 article EN Cancer Research 2012-11-14

Abstract Tyrosine kinase signalling within cancer cells is central to the establishment of an immunosuppressive microenvironment. Although tyrosine inhibitors act, in part, augment adaptive immunity, increased heterogeneity and functional redundancy kinome a hurdle achieving durable responses immunotherapies. We previously identified Shc1 (ShcA) scaffold, regulator signalling, as essential for promoting breast immune suppression. Herein we show that ShcA pathway simultaneously activates...

10.1038/ncomms14638 article EN cc-by Nature Communications 2017-03-09
Coming Soon ...